SME · BSE SMEListed

SPECIALITY MEDICINES LIMITED IPO: dates, price band, lot size, objects of the issue

Get analyst updates on this IPO

Analyst updates come by email.

What changed since listing, from SEBI-registered research analysts.

By continuing you agree to the Terms and Privacy policy

Updated Tue 17 Nov 2026, 10:51 am IST · Source: Prospectus dated Wed 25 Mar 2026

Bid dates
Fri 20 Mar 2026 to Tue 24 Mar 2026
Listing date
Mon 30 Mar 2026
Issue price
₹124 per share

Listed on BSE on Mon 30 Mar 2026.

Listing price ₹124

Opening price on BSE on the listing day (BSE daily price file for Mon 30 Mar 2026)

This page is now frozen. Facts stay as filed; the quote is on the exchange.

Key facts

Issue price
₹124 per share
Prospectus dated Wed 25 Mar 2026, page 2
Lot size
Not stated in the prospectus
Prospectus dated Wed 25 Mar 2026
Lot amount at the upper band
Not stated in the prospectus
Prospectus dated Wed 25 Mar 2026
Issue size at the upper band
₹29.14 crore
Fresh issue
₹29.14 crore
Prospectus dated Wed 25 Mar 2026, page 1
Offer for sale
None
Prospectus dated Wed 25 Mar 2026, page 1
Bid dates
Fri 20 Mar 2026 to Tue 24 Mar 2026
Prospectus dated Wed 25 Mar 2026, page 2
Listing date
Mon 30 Mar 2026
BSE daily price file for Mon 30 Mar 2026
Anchor lock-in ends
Not stated in the prospectus
Prospectus dated Wed 25 Mar 2026
Risk factors
73
Prospectus dated Wed 25 Mar 2026, page 55

Timeline (IST)

  1. OpensFri 20 Mar 2026, 10:00 am IST confirmedProspectus dated Wed 25 Mar 2026, page 2
  2. ClosesTue 24 Mar 2026 confirmedProspectus dated Wed 25 Mar 2026, page 2
  3. UPI mandate cut-offNot stated in the prospectus Prospectus dated Wed 25 Mar 2026
  4. AllotmentWed 25 Mar 2026 by T+3 schedule
  5. Refund and unblockFri 27 Mar 2026 by T+3 schedule
  6. Shares to dematFri 27 Mar 2026 by T+3 schedule
  7. ListingMon 30 Mar 2026 confirmedBSE daily price file for Mon 30 Mar 2026

Objects of the issue

ObjectAmount
Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje: Manda, Tal. Umargam, Dist. Valsad, Gujarat₹12.68 crore
Product Registration in International Markets and Product Development for sale in international markets₹2.99 crore
Funding for Marketing and Promotional Activities₹1.66 crore
To Meet Working Capital Requirements.₹8.00 crore
General Corporate Purposes₹25.00 lakh
Total₹25.58 crore

Prospectus dated Wed 25 Mar 2026, page 87

Company and promoters

As described in the prospectus

We are engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.

Prospectus dated Wed 25 Mar 2026, page 22

Promoters

  • 2 individual promoters

Prospectus dated Wed 25 Mar 2026, page 22

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group59.67%43.26%

Prospectus dated Wed 25 Mar 2026, page 82

Financials (restated)

ItemOctober 31, 2025March 31, 2025March 31, 2024March 31, 2023
Revenue from operations₹36.72 crore₹58.27 crore₹27.52 crore₹23.18 crore
Profit after tax₹6.06 crore₹8.61 crore₹2.93 crore₹1.70 crore
Net worth₹36.47 crore₹30.42 crore₹15.06 crore₹5.93 crore
Total borrowingsNot stated in the prospectusNot stated in the prospectusNot stated in the prospectusNot stated in the prospectus

Prospectus dated Wed 25 Mar 2026, page 60

SME issue facts

  • The face value of each Equity Share is ₹ 10 and the Issue Price at the lower end of the Price Band is ₹ 117 per Equity Share and at the higher end of the Price Band is ₹ 124 per Equity Share. (Prospectus dated Wed 25 Mar 2026, page 315)
  • the minimum contract size of 1000 Equity Shares (Prospectus dated Wed 25 Mar 2026, page 316)
  • Allocation and allotment of Equity Shares through this Issue was done in multiples of 1000 Equity Share subject to a minimum allotment of 1000 Equity Shares to the successful Applicants. (Prospectus dated Wed 25 Mar 2026, page 316)
  • the minimum application size in terms of number of specified securities was not less than two lots. (Prospectus dated Wed 25 Mar 2026, page 316)
  • the minimum number of allottees in this Issue was 200 shareholders. (Prospectus dated Wed 25 Mar 2026, page 316)

Peer comparison (as in the Prospectus)

Name of the CompanyFace value (₹)Revenue from operations (₹ in Lakhs)Basic EPS (₹)Diluted EPS (₹)P/E (based on Diluted EPS)Return on net worth (%)NAV per Equity Shares (₹)
Speciality Medicines Limited105,827.1414.1014.108.7928.42%47.26
Remus Pharmaceuticals Limited1062,036.0065.2165.2110.4115.02%434.25
Trident Lifeline Limited108,696.4710.2210.2227.0018.23%56.05
Mono Pharmacare Limited1016,834.491.751.757.499.90%17.66

Reproduced from the Prospectus dated Wed 25 Mar 2026, pages 114 to 115; InsightPier adds no figures

Risk factors

73 total
  1. Dependence on third-party suppliers for products (offer document page 29)
  2. Revenue concentrated among major customers (offer document page 29)
  3. Past negative operating cash flows (offer document page 30)
  4. No prior research and development experience (offer document page 31)
  5. Risks from international operations (offer document page 33)

All 73 risk factors, pages 28 to 55

Offer document

Allotment and bids

Registrar to the issue: SKYLINE FINANCIAL SERVICES PRIVATE LIMITED.

Allotment status was expected on the registrar's site from Wed 25 Mar 2026 and is not yet confirmed. Pick "SPECIALITY MEDICINES LIMITED" from the issue list there.

Subscription (final)

CategoryShares offeredShares bid forTimes subscribed
Overall––2.34×

ipocentral.in and ipowatch.in, as of Tue 17 Nov 2026

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts